Zelboraf Alternatives Compared
| Zelboraf (vemurafenib) | Yervoy (ipilimumab) | Mekinist (trametinib) |
|
|---|
| Zelboraf (vemurafenib) | Yervoy (ipilimumab) | Mekinist (trametinib) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Erdheim-Chester Disease, Melanoma - Metastatic. Zelboraf may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Melanoma - Metastatic, Renal Cell Carcinoma, Colorectal Cancer, Malignant Pleural Mesothelioma, Melanoma. Yervoy may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Melanoma - Metastatic, Low-Grade Glioma, Non Small Cell Lung Cancer, Solid Tumors, Thyroid Cancer. Mekinist may also be used for purposes not listed in this medication guide. |
Related suggestions Melanoma, Metastatic
Popular comparisons
|
|||||||||||||||||||||||
| More about Zelboraf (vemurafenib) | More about Yervoy (ipilimumab) | More about Mekinist (trametinib) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Zelboraf has an average rating of 6.3 out of 10 from a total of 4 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 25% reported a negative effect. |
Yervoy has an average rating of 9.5 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Mekinist has an average rating of 7.3 out of 10 from a total of 3 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 33% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Zelboraf side effects |
View all Yervoy side effects |
View all Mekinist side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Zelboraf prices |
View all Yervoy prices |
View all Mekinist prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
120 hours |
352.8 hours |
115.2 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 624 drugs are known to interact with Zelboraf:
|
A total of 660 drugs are known to interact with Yervoy:
|
A total of 33 drugs are known to interact with Mekinist:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
August 17, 2011 |
March 25, 2011 |
May 29, 2013 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Alecensa
Alecensa (alectinib) is an oral kinase inhibitor that may be used to treat certain types of ...
Alunbrig
Alunbrig (brigatinib) is used to treat anaplastic lymphoma kinase-positive (ALK+) metastatic ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Augtyro
Augtyro (repotrectinib) is a next-generation TKI (Tyrosine Kinase Inhibitor) cancer medicine used ...
Ayvakit
Ayvakit (avapritinib) is a prescription medicine used for the treatment of gastrointestinal stromal ...
Balversa
Balversa (erdafitinib) is an oral kinase inhibitor that may be used to treat adults with locally ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
Cabometyx
Cabometyx is used to treat advanced kidney cancer, liver cancer, thyroid cancer, and pancreatic and ...
Caprelsa
Caprelsa (vandetanib) is used to treat thyroid cancer that cannot be removed by surgery or that has ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.